The Prognostic Value of Baseline Hematological Parameters of Peripheral Blood in Metastatic Gastric Cancer Treated with Apatinib

There is strong evidence that apatinib is effective in the treatment of third- or later-line advanced metastatic gastric cancer (mGC). Hematology prediction index is a convenient and cheap method to predict the prognosis of disease. However, the prognosis of baseline hematological parameters of peripheral blood, such as neutrophil-to-lymphocyte ratio (NLR), carbohydrate antigen 125 (CA125) and albumin (ALB) on mGC treated with apatinib have not been identified. We retrospectively analyzed mGC received apatinib between 1 January 2014 and 30 June 2021. Survival analyses were performed using the Kaplan-Meier method and Cox-proportional hazards model. A total of 117 patients were included in this study. The cutoff value of NLR, CA125 and ALB was 2.25, 19.24 U/ml and 37.60 g/L, respectively. The disease control rates (DCR) in the high and low NLR groups were 52.94% and 73.47% (=0.024); 48.28% and 74.58% (=0.003) in high and low CA125 groups; 72.97% and 41.86% (=0.001) in high and low ALB groups. By survival analysis, increasing NLR (=0.003), CA125 (<0.001) and decreasing ALB (<0.001) predicted a shorter PFS after apatinib. NLR (=0.015), CA125 (=0.004) and ALB (=0.005) were significantly predictors for PFS in mGC treated with aptinib. Increasing NLR, CA125 and decreasing ALB were associated with poorer clinical efficiency and prognosis after apatinib treatment.